Bradley-B-Cell-paper-300x284ME/CFS with 33 matched healthy controls. They did a detailed analysis of B cell subsets and founded changes that suggest “a subtle tendency to autoimmunity.” “The CFS cohort had significantly greater proportions of transitional B cells, naive B cells and reduced proportions of plasmablasts expressed as a percentage of B cells. B cells produce antibodies and are potent antigen presenting cells. Impairment of B cell function or development leads to recurrent infections, or a propensity to autoimmunity or allergy.” They were prompted to conduct the study based on the promising 2011 report of Rituximab therapy leading to improved symptoms in 10 of 15 CFS patients. (Clinical & Experimental Immunology, Apr. 2013)